Taconic Biosciences Announces Release of New Parkinson's Disease Animal Model
(Thomson Reuters ONE) -
HUDSON, N.Y., April 25, 2017 (GLOBE NEWSWIRE) -- Taconic Biosciences, a global
leader in genetically engineered mouse models and associated services, announced
that effective April 17, 2017, in conjunction with The Michael J. Fox Foundation
for Parkinson's Research (MJFF), began commercial distribution of a new
Parkinson's disease mouse Model 13940 (C57BL/6- Lrrk2tm4.1Arte).
The development of Model 13940 underscores the commitment of both Taconic and
MJFF to provide novel models for expediting Parkinson's disease testing.
Model 13940 is a constitutive Knock-In (KI)/conditional Knock-Out (KO) of the
mouse LRRK2 gene. The human G2019S point mutation has been introduced into exon
41 of the mouse LRRK2 gene. Additionally, exon 41 is flanked by lox P sites to
generate a constitutive KO of the LRRK2 gene upon intercrossing with a Cre
deleter strain.
* The G2019S alpha-mutation is linked to the development of Parkinson's
disease, both sporadic and familial(1).
* In patients, the G2019S LRRK2 mutation is an autosomal dominant mutation
that leads to pathology similar to what is observed with idiopathic
Parkinson's disease.
* At 18 months of age, LRRK2 G2019S mice show an increased locomotor response
after amphetamine challenge.
* This knock-in mutation does not appear to affect basal motor function or
more complex behavior in C57Bl6 mice.
Dr. Michael Seiler, Taconic Biosciences' portfolio director for commercial
genetically engineered models, shared, "Parkinson's disease affects 1 in 100
people over the age of 60 (https://www.michaeljfox.org/understanding-
parkinsons/living-with-pd/topic.php?causes&navid=causes). This model provides
researchers throughout the world a novel tool to help find a cure for this
devastating disease."
Dr. Nicole Polinski, associate director of the pre-clinical tools and animal
models portfolios at The Michael J. Fox Foundation commented: "Providing
researchers with open access to pre-clinical models is an important investment
for speeding research into the pathology and treatment of Parkinson's disease.
This model in particular is novel and advantageous in that it is a targeted
mutation with endogenous regulation and may therefore recapitulate the G2019S
LRRK2-related pathological mechanisms of this clinically-relevant mutation."
Model 13940 is produced and distributed under rights to patents and/or
intellectual property owned by and licensed to MJFF and Taconic. Taconic has
rights to distribute the model on behalf of MJFF. MJFF permits the sale to each
purchaser that agrees to the Terms and Conditions of the sale. This model is
produced in state-of-the-art facilities at the Murine Pathogen Free(TM)
(MPF(TM)) health status.
To learn more about this new Parkinson's disease model, please contact Taconic
Biosciences at 1-888-TACONIC (888-822-6642) in the US, +45 70 23 04 05 in Europe
or at info(at)taconic.com.
Reference
1 P.Matikainen-Ankney BA, et al. 2016. Altered Development of Synapse Structure
and Function in Striatum Caused by Parkinson's Disease-Linked LRRK2-G2019S
Mutation. J Neurosci. Jul 6; 36(27): 7128-7141. PMID: 27383589
About Taconic Biosciences, Inc.
Taconic Biosciences is a fully-licensed, global leader in genetically engineered
rodent models and services. Founded in 1952, Taconic helps biotechnology
companies and institutions acquire, custom generate, breed, precondition, test,
and distribute valuable research models worldwide. Specialists in genetically
engineered mouse and rat models, precision research mouse models, and integrated
model design and breeding services, Taconic operates three service laboratories
and six breeding facilities in the U.S. and Europe, maintains distributor
relationships in Asia and has global shipping capabilities to provide animal
models almost anywhere in the world.
Media Contact:
Kelly Owen Grover
Director of Marketing Communications
(518) 697-3824
kelly.grover(at)taconic.com
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Taconic Biosciences via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 25.04.2017 - 19:09 Uhr
Sprache: Deutsch
News-ID 538243
Anzahl Zeichen: 4813
contact information:
Town:
Hudson
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 299 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Taconic Biosciences Announces Release of New Parkinson's Disease Animal Model"
steht unter der journalistisch-redaktionellen Verantwortung von
Taconic Biosciences (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
